Literature DB >> 3905414

The pharmacokinetics and haemodynamics of BTS 49 465 and its major metabolite in healthy volunteers.

R D Wynne, E L Crampton, I D Hind.   

Abstract

The pharmacokinetic and haemodynamic effects of a 200 mg oral dose of BTS 49 465 (7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone) were investigated in a double-blind placebo controlled study. BTS 49 465 was rapidly absorbed and cleared from the systemic circulation with a half-life of 1.6 h by oxidation to the sulphone metabolite. The metabolite was cleared with a half-life of 37.6 h. Saliva concentrations of both BTS 49 465 and its metabolite correlated well with the plasma concentrations. Compared to placebo, BTS 49 465 produced statistically significant reductions in blood pressure and increases in heart rate both supine and after a 60 degrees head up tilt. The time course of the haemodynamic changes suggested that the sulphone metabolite contributed to the overall hypotensive response. Plasma Renin Activity was only marginally elevated and there was no evidence of acute fluid retention. BTS 49 465 was well tolerated in terms of haematological and biochemical parameters and subjective side-effects.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3905414     DOI: 10.1007/bf00607911

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  2 in total

1.  Hydralazine and plasma renin activity.

Authors:  H Ueda; S Yagi; Y Kaneko
Journal:  Arch Intern Med       Date:  1968-11

2.  The effects of BTS 49465 on blood pressure and peripheral arteriolar and venous tone in normal volunteers.

Authors:  A J Cowley; R D Wynne; J R Hampton
Journal:  J Hypertens Suppl       Date:  1984-12
  2 in total
  14 in total

1.  Flosequinan for congestive heart failure: what promise does it hold?

Authors:  J R Hampton
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

2.  Duration and reproducibility of initial hemodynamic effects of flosequinan in patients with congestive heart failure.

Authors:  G L Bartels; W J Remme; A C Wiesfeld; F J Kok; M P Look; X H Krauss; H A Kruyssen
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

3.  Lack of effect of flosequinan on the pharmacokinetics of theophylline.

Authors:  F Kamali; C Edwards; M D Rawlins
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

4.  Exercise capacity, hemodynamic, and neurohumoral changes following acute and chronic administration of flosequinan in chronic congestive heart failure.

Authors:  G A Riegger; H Kahles; A Wagner; E P Kromer; D Elsner; K Kochsiek
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

5.  Possible role of metabolite in flosequinan-related mortality.

Authors:  F Kamali; C Edwards
Journal:  Clin Pharmacokinet       Date:  1995-12       Impact factor: 6.447

6.  A comparison of the effects of flosequinan, a new vasodilator, and propranolol on sub-maximal exercise in healthy volunteers.

Authors:  H M Lewis; M J Kendall; S R Smith; J R Bratty
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

7.  Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects.

Authors:  A J Cowley; R D Wynne; K Stainer; L Fullwood; J M Rowley; J R Hampton
Journal:  BMJ       Date:  1988-07-16

8.  The effects of flosequinan on regional blood flow in normal man.

Authors:  R A Scott; K L Woods; D B Barnett
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

9.  Studies on the cardiac actions of flosequinan in vitro.

Authors:  R W Gristwood; J Beleta; J Bou; I Cardelús; A G Fernández; J Llenas; P Berga
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

10.  Differential inotropic effects of flosequinan in ventricular muscle from normal ferrets versus patients with end-stage heart failure.

Authors:  C L Perreault; N L Hague; E Loh; I M Hunneyball; M F Sim; J P Morgan
Journal:  Br J Pharmacol       Date:  1992-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.